SCHEMBL6421076

SCHEMBL6421076

Clc1ccc(-c2ccc(/C=N\Nc3nc4nonc4nc3NCc3ccccc3)o2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.50
BIRC5 O15392 1/20 0.45
ALDH1A1 P00352 8/20 0.44
KMT2A Q03164 7/20 0.44
MEN1 O00255 6/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TLR9 Q9NR96 1/20 0.44
KDM4E B2RXH2 5/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HPGD P15428 6/20 0.42
GAA P10253 3/20 0.42
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42
HTT P42858 3/20 0.41
PHGDH O43175 1/20 0.41
NPSR1 Q6W5P4 3/20 0.41
ALOX12 P18054 1/20 0.41
S1PR2 O95136 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421081 1.00 MAPT (0.50) MAPTBIRC5ALDH1A1KMT2AMEN1
SCHEMBL6510185 0.93 BIRC5 (0.50) MAPTBIRC5ALDH1A1KMT2AMEN1
SCHEMBL6419253 0.88 PHGDH (0.57) MAPTBIRC5ALDH1A1KMT2AMEN1
SCHEMBL6419258 0.88 PHGDH (0.57) MAPTBIRC5ALDH1A1KMT2AMEN1
SCHEMBL6414397 0.85 ALDH1A1 (0.56) MAPTBIRC5ALDH1A1KMT2AMEN1
SCHEMBL6435175 0.82 BIRC5 (0.68) MAPTBIRC5ALDH1A1KMT2AMEN1
SCHEMBL6435171 0.82 BIRC5 (0.68) MAPTBIRC5ALDH1A1KMT2AMEN1
SCHEMBL6412944 0.81 PRMT5 (0.50) MAPTBIRC5ALDH1A1KMT2AMEN1
SCHEMBL6412951 0.81 PRMT5 (0.50) MAPTBIRC5ALDH1A1KMT2AMEN1
SCHEMBL6432659 0.81 BIRC5 (0.59) MAPTBIRC5ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885BIRC5 2525/4885ALDH1A1 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.